Apimeds Pharmaceuticals US Inc. Common Stock (APUS)
Stock · AMEX · Health Care
$4as of 10/16/2026
Price chart
Active signals
APUS Signal Track Record
How signals performed across all stocks →What APUS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 4 | -37.8% | 0% | October 5, 2026 |
| Bollinger Band Breakdown | 3 | -20.3% | 33% | August 27, 2026 |
| Any 20-session window (baseline) | -25.3% | 26% |
Computed by MarketWall from daily closing prices since February 25, 2026. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About APUS
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.apimedsus.com/
Fundamentals
- 1-day range
- $3.9$4.35
- Market cap
- $7.29M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-36.71
- Dividend yield
- —
- Beta
- 3.40
- Avg. volume
- 3.82M
Apimeds Pharmaceuticals US Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- APUSApimeds Pharmaceuticals US Inc. Common Stock$4.04▼ 7.97%Market cap $7.29MP/E —$1.51$403.1
- ADXNAddex Therapeutics Ltd American Depositary Shares$2.76▼ 8.61%Market cap $7.34MP/E —$0.018$0.069
- BOLTBolt Biotherapeutics Inc. Common Stock$4▼ 5.66%Market cap $7.44MP/E —$3.1$7.2
- MTVAMetaVia Inc. Common Stock$1.26▼ 8.03%Market cap $7.49MP/E —$0.9661$14.85
- MBRXMoleculin Biotech Inc. Common Stock$0.28▼ 24.32%Market cap $7.50MP/E —$0.1614$15.75
- XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares$1.96▲ 2.62%Market cap $7.05MP/E —$1.6$11.8
- CANFCan-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares$1.76▼ 4.86%Market cap $7.63MP/E —$299$9,000,000
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| APUS Apimeds Pharmaceuticals US Inc. Common Stock | $7.29M | — | $4.04 | ▼ 7.97% | $1.51$403.1 |
| ADXN Addex Therapeutics Ltd American Depositary Shares | $7.34M | — | $2.76 | ▼ 8.61% | $0.018$0.069 |
| BOLT Bolt Biotherapeutics Inc. Common Stock | $7.44M | — | $4 | ▼ 5.66% | $3.1$7.2 |
| MTVA MetaVia Inc. Common Stock | $7.49M | — | $1.26 | ▼ 8.03% | $0.9661$14.85 |
| MBRX Moleculin Biotech Inc. Common Stock | $7.50M | — | $0.28 | ▼ 24.32% | $0.1614$15.75 |
| XTLB XTL Biopharmaceuticals Ltd. American Depositary Shares | $7.05M | — | $1.96 | ▲ 2.62% | $1.6$11.8 |
| CANF Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares | $7.63M | — | $1.76 | ▼ 4.86% | $299$9,000,000 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Apimeds Pharmaceuticals US' Subsidiary Mindwave Innovations Signs Three Agreements Between Sept. 24 And Oct. 4, 2026, To Build And Operate Dedicated Blockchain Networks For Clients In Climate Finance, Sports Media And Insurancebenzinga · 10/9/2026
- Apimeds Pharmaceuticals US' Subsidiary Mindwave Innovations Signs Three Agreements Between Sept. 24 And Oct. 4, 2026, To Build And Operate Dedicated Blockchain Networks For Clients In Climate Finance, Sports Media And InsuranceBenzinga · 10/9/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 10/9/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 10/7/2026
- What's going on in today's sessionChartMill · 10/6/2026
- Top movers in Tuesday's sessionChartMill · 10/6/2026
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · 10/6/2026
- Monday's session: top gainers and losersChartMill · 10/5/2026
- Keep an eye on the top gainers and losers in Monday's session.ChartMill · 10/5/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Apimeds Subsidiary Signs Deal With Flash Sports & Media
Apimeds Pharmaceuticals announced that its subsidiary, MindWave, has signed a 12-month agreement with Flash Sports & Media. The partnership involves building and operating a project called FlashChain. This move highlights the company's ongoing expansion into software development and technology services beyond its core pharmaceutical operations.
Apimeds Subsidiary Signs Deal With Flash Sports & Media. Apimeds Pharmaceuticals announced that its subsidiary, MindWave, has signed a 12-month agreement with Flash Sports & Media. The partnership involves building and operating a project called FlashChain. This move highlights the company's ongoing expansion into software development and technology services beyond its core pharmaceutical operations.